Clinical trial NCT00182663 (phase 2, status: completed)
Conditions: refractory multiple myeloma, stage i multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma
ICD codes: D46.4, D46.1, D46.A, D46.0, D46.20, D46.21, D46.22, C90.01, C90.02, C90.00, C90.01, C90.02, C90.00, C90.01, C90.02, C90.00
Drugs: clarithromycin, thalidomide, dexamethasone
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Any autologous or syngeneic patient who underwent high dose melphalan (>= 140 mg/m^2)
             therapy/peripheral blood stem cell (PBSC) or bone marrow (BM) rescue for any stage of
             multiple myeloma and did not participate in another clinical transplant trial which is
             also evaluating disease free survival or survival

          -  Platelet count (transfusion independent) > 50,000 cells/mm^3 for 5 calendar days after
             recovery from high dose

          -  Absolute granulocyte count > 1500 cells/mm^3 for 5 calendar days after recovery from
             high dose

          -  Patients will start therapy between 30 days to 120 days after transplant

          -  Willingness and ability to comply with Food and Drug Administration (FDA)-mandated
             S.T.E.P.S. (Celgene System for Thalidomide Education and Prescribing Safety) Program

          -  Signing a written informed consent form

        Exclusion Criteria:

          -  Karnofsky score less than 70

          -  A left ventricular ejection fraction less than 45%; patients with congestive heart
             disease, history of myocardial infarction (MI), or coronary artery disease

          -  Total bilirubin greater than 2 mg/ml (unless history of Gilbert's disease)

          -  Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase
             (SGPT) > 2.5 x upper limit of normal

          -  History of deep venous thrombus, arterial occlusions, or pulmonary emboli

          -  Pregnant and/or lactating females

          -  Patients who cannot give informed consent

          -  Patients with untreated systemic infection

          -  Patients with history prior to transplant of treatment with combination therapy
             Thalidomide/Biaxin and Steroid without response

          -  Patients allergic to Thalidomide, Biaxin or Dexamethasone

          -  Referring physician not registered with S.T.E.P.S. program or unwilling to oversee the
             care of the patients on study and comply with the FDA-mandated S.T.E.P.S. Program

          -  Patients unwilling to practice adequate forms of contraception if clinically
             indicated; male patients on study need to be consulted to use latex condoms even if
             they have had a vasectomy every time they have sex with a woman who is able to have
             children while they are being treated and for four weeks after stopping drugs

          -  Patients with history of seizures